NeoBiotechnologies develops extensively validated antibodies, with particular attention to specificity, sensitivity and reproducibility. Based on a guide by NeoBiotechnologies, this article explores why antibody validation is essential and the different methods used to assess antibody performance.
Antibodies are essential tools in life science research, supporting a wide range of applications, including western blotting, flow cytometry, immunohistochemistry and immunofluorescence. However, even a carefully planned experiment can produce unreliable results when an antibody has not been adequately validated. Antibody validation therefore plays an important role in helping researchers generate accurate, reproducible and biologically relevant data.
Antibody validation involves confirming that an antibody recognises its intended target specifically and performs consistently in the application for which it is designed. Although many antibodies are described as validated, the extent and methods of validation can differ significantly between manufacturers. Understanding how antibodies are evaluated, and which methods provide reliable evidence of specificity, helps researchers make informed decisions and reduce the risk of experimental setbacks.
Reliable antibody performance is essential for producing trustworthy research results. When an antibody specifically recognises its intended target, researchers can interpret detected signals with greater confidence, whether they are investigating protein expression, abundance or localisation.
However, antibodies may also interact with unrelated proteins, potentially leading to inaccurate conclusions and difficulties reproducing experimental findings.
Traditionally, some antibodies have been evaluated primarily on their ability to detect the expected target, without extensive investigation of potential cross-reactivity or off-target interactions. Consequently, an antibody may appear to perform correctly while also recognising additional proteins in a sample.
These unwanted interactions can contribute to background signals, unexpected staining patterns and misleading experimental results.
Increasing attention to reproducibility in scientific research has encouraged manufacturers and researchers to adopt more comprehensive validation strategies. Rather than depending on a single experiment, antibody validation increasingly combines different techniques to assess both target specificity and performance in relevant applications.
A fundamental question in antibody validation is whether an antibody recognises the intended protein without significant binding to other targets.
Determining specificity can be challenging because many proteins share structural similarities. Antibodies may recognise related members of a protein family, different isoforms or unrelated proteins containing similar epitopes. Without sufficient testing, such interactions may remain undetected.
To investigate these potential interactions, antibody manufacturers increasingly use advanced screening technologies that evaluate binding against large numbers of proteins simultaneously.
These methods provide a broader assessment of antibody specificity compared with testing against a single target and can help identify potential cross-reactivity during antibody development.
The objective is therefore not only to confirm that an antibody recognises the correct protein, but also to assess whether it interacts with unintended targets under relevant experimental conditions.
Human proteome microarrays offer an extensive approach to evaluating antibody specificity.
These platforms contain thousands of recombinant human proteins immobilised on a single slide, enabling antibody binding to be examined across a broad range of potential targets.
By screening an antibody against many proteins in parallel, researchers can detect potential off-target interactions that may not be identified through conventional validation methods.
This provides valuable additional evidence of specificity, particularly when evaluating antibodies intended for applications where non-specific binding can influence experimental outcomes.
Proteome-wide screening is especially relevant for sensitive techniques such as flow cytometry, immunofluorescence and biomarker research, where even limited cross-reactivity may complicate the interpretation of results.
With reproducibility becoming an increasingly important consideration in life science research, comprehensive specificity assessment represents a valuable part of antibody quality evaluation.
Specificity alone does not guarantee that an antibody will perform successfully in every experimental technique.
An antibody may work effectively in one application but be unsuitable for another because the target protein can be presented in different conformations or biological environments.
In western blotting, for example, proteins are generally denatured and separated according to molecular weight. Immunohistochemistry, on the other hand, requires antibodies to recognise proteins within preserved tissue structures. Flow cytometry often involves detecting proteins in their native conformation on or within individual cells.
These differences make application-specific validation essential.
Manufacturers therefore use various experimental approaches to demonstrate how antibodies perform under the conditions associated with their intended applications.
Western blotting is widely used to evaluate antibody performance and target recognition.
During validation, an antibody is expected to detect the target protein at its anticipated molecular weight while producing minimal non-specific bands.
Consistent and clearly defined banding patterns provide useful evidence that the antibody can recognise the intended protein within a complex sample.
Western blot data therefore often serve as an important initial indication of antibody performance, particularly when assessing specificity in protein analysis.
Flow cytometry requires antibodies that can accurately identify proteins expressed by individual cells.
Even relatively low levels of non-specific binding may interfere with the identification and interpretation of cell populations, making appropriate antibody validation particularly important.
Validation typically examines whether an antibody can distinguish target-positive cells from negative populations while maintaining minimal background staining.
Reliable performance in these conditions supports accurate cell phenotyping and biomarker analysis.
Immunohistochemistry (IHC) and immunofluorescence (IF) are used to investigate protein expression and localisation within cells and tissues.
For these applications, validation focuses on whether an antibody produces staining patterns consistent with the expected biological distribution of its target.
This is particularly important when protein localisation contributes to the interpretation of experimental results.
Appropriate validation helps researchers assess whether observed staining reflects genuine target expression rather than unintended antibody interactions, improving confidence in tissue and cell imaging studies.
Tissue microarrays (TMAs) provide an efficient method for evaluating antibody performance across multiple tissue types.
By incorporating numerous tissue samples onto a single slide, these platforms allow researchers to compare staining patterns and investigate antibody specificity under consistent experimental conditions.
An important advantage is that tissues with expected positive and negative expression can be assessed alongside one another. This makes it easier to identify unexpected staining patterns and potential cross-reactivity.
Tissue microarrays can also provide information about antibody sensitivity by demonstrating whether the antibody detects proteins expressed at physiologically relevant levels.
For these reasons, TMAs are a valuable component of comprehensive antibody validation strategies, particularly for immunohistochemistry applications.
Antibody validation should not be considered complete once specificity and application performance have been demonstrated.
Consistency across production batches is also important, especially for research projects that depend on reliable antibody performance over extended periods.
Batch-to-batch variation can influence experimental outcomes and make it more difficult to reproduce findings.
To address this, manufacturers may implement additional quality-control procedures, including antibody sequence verification.
Sequence verification helps confirm that antibodies produced in subsequent batches retain the identity of the original validated clone, supporting consistency throughout production.
For researchers involved in long-term studies or clinical biomarker validation, these quality-control measures provide an additional level of confidence in antibody reliability.
Antibody quality has a direct influence on experimental reliability, making thorough validation an essential consideration when selecting research reagents.
Effective antibody validation extends beyond confirming that an antibody recognises its intended target. It also involves assessing potential cross-reactivity, demonstrating performance in relevant applications and implementing quality-control measures that support reproducibility.
Modern validation techniques, including proteome-wide screening, tissue microarrays and application-specific testing, provide researchers with more comprehensive information about antibody performance.
By selecting antibodies supported by appropriate validation data, researchers can minimise experimental uncertainty, improve reproducibility and generate results with greater confidence.
At Sanbio, we support researchers in selecting antibodies that meet their experimental requirements, combining access to the NeoBiotechnologies portfolio with scientific expertise and technical guidance.
Try it. Trust it. Get 10% off NeoBiotechnologies antibodies for a limited time.
References
Sikorski, K., Mehta, A., Inngjerdingen, M. et al. A high-throughput pipeline for validation of antibodies. Nature Methods 15, 909–912 (2018). https://doi.org/10.1038/s41592-018-0179-8
Uhlen, M., Bandrowski, A., Carr, S. et al. A proposal for validation of antibodies. Nature Methods 13, 823–827 (2016). https://doi.org/10.1038/nmeth.3995